254 Results
VeriStrat test saved an average of $1,050 per patient while improving survival outcomes (as compared to patients treated without the use of the test).
Biodesix recently added Biognosys' Proteomics to their capabiltites.
Biodesix, Inc and Inivata announced a partnership today to develop and commercialize Next Generation Sequencing (NGS)-blood based tests for lung cancer.
The paper’s authors conclude that using VeriStrat improves overall survival and decreases medical costs in the US payer system.
A new study published in Current Medical Research and Opinion shows that VeriStrat changes treatment decisions for patients with lung cancer.
Biodesix data on proteomic and genomic blood-based assays presented at EORTC
Biodesix and Bioyong announced a $38M deal for development and commercialization of VeriStrat in China.
Biodesix announced that the VeriStrat® test is now considered a medically necessary benefit by Aetna Corporation.
Biodesix's GeneStrat liquid biopsy test now includes ROS1 and RET mutations. The test helps physicians make treatment decisions for cancer patients.
Biodesix and Progenetics have entered into an international agreement; Biodesix tests will be available in Israel for the first time.